Business Insights, Advance Technology, Size, Share, Trends, segments opportunities and Forecast to 2026

SEATTLE, March 29, 2021, (PHARMIWEB) — Acute Lymphoblastic Leukemia Therapeutics Market Insights

Acute lymphoblastic leukemia (ALL) is a cancer of bone marrow and blood that is caused due to uncontrolled generation of lymphoblast, which are immature white blood cells (WBCs). Renal failure, pneumonia, respiratory distress, and bone pain are some of the common symptoms of ALL. The progression rate is high in ALL and the condition may lead to death within few months, if left untreated. Lymphoblast malfunction and accumulate around healthy cells. In ALL, the bone marrow loses the ability to form sufficient numbers of red blood cells (RBCs), white blood cells, and platelets, which may often lead to recurrent infections, anemia, bleeding and bruising. The tumor can spread to other parts of the body including lymph nodes, liver, spleen, and the central nervous system. ALL is highly prevalent in children and requires timely treatment and diagnosis for better outcome.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1606

According to the World Health Organization (WHO), ALL is classified based on three different sub-types according to the lymphocyte or white blood cell that has transformed into cancerous cell. The precursor B cell ALL is most common in adults. The mature B cell ALL is characterized by particular genetic changes and precursor T cell ALL is common in young adults and men.

High prevalence of ALL to augment the market growth

Increasing prevalence of ALL and growing link of the condition with genetic disorders such as Down’s syndrome is a major factor boosting growth of the acute lymphoblastic leukemia therapeutics market growth. For instance, according to the Healthline Media UK Ltd., 2017, ALL accounts for 80% of childhood leukemia and is the most common type of cancer and leukemia in children under five years of age than in adults, mostly affecting children aged 2 to 3 years. Moreover, according to the survey by MedicineNet, a medical information portral, about two-thirds of acute leukemia diagnosed in children are associated with Down’s syndrome, thus increasing the likelihood of children affected with genetic disorders to develop ALL. High exposure to toxins- benzene and radiations such as X-rays before birth is also expected to contribute to growth of the market.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000

Buy Now this Premium Report to Grow your Business @ https://bit.ly/3w4TKLE

Key players in the market are focused on approval and launch of new products to expand their product portfolio, which is expected to propel growth of the market. For instance, in August 2017, the U.S. Food and Drug Administration approved chimeric antigen receptor T cell (CAR-T) therapy, Kymriah (tisagenlecleucel) manufactured by Novartis Pharmaceuticals Corporation. The therapy is indicated for patients up to 25 years of age with relapsed or refractory B-cell precursor ALL.

Increasing focus of public and private organizations on R&D of novel therapeutics for the treatment of ALL is expected to boost growth of the market. For instance, the Leukemia and Lymphoma Society (LLS) has funded over US $ 1.2 Billion in cutting-edge research to develop cure for blood cancer. LLS is also focused on improving the lives of patients by providing free information and support services.

Some of the factors that hinder growth of the market include high treatment cost and adverse effects of the CAR-T cell therapies. For instance, according to the survey by American Journal of Managed Care (AJMC), February 2018, the initial treatment cost of for the approved CAR-T cell therapies developed by Novartis AG is around US$ 475,000 per patient.

To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1606

North America is expected to account for the largest market share in the global acute lymphoblastic leukemia therapeutics market

On the basis of region, the global acute lymphoblastic leukemia therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The market in North America is expected to account for the largest market share over the forecast period. This is attributed to factors such as high prevalence of ALL and increasing number of organizations undertaking clinical trials for the disease. For instance, according to the American Cancer Society, 2016, an estimated 5,970 new ALL diagnoses and 1,440 deaths from ALL were registered in 2017. Moreover, according to the St. Jude Children’s Research Hospital, about 3,000 people aged below 20 years are found to have acute lymphoblastic leukemia each year in the U.S.

Moreover, the St. Jude Children’s Research Hospital, U.S. is focusing on improving outcomes for children with leukemia by undertaking clinical trials to develop novel therapeutics for the condition. For instance, in 2012, the St. Jude Children’s Research Hospital initiated trials for ALLR18 for pediatric relapsed or refractory precursor B-cell acute lymphoblastic leukemia. Moreover, in 2015, Juno Therapeutics, Inc. developed JCAR015 (CD19-targeted CAR T cells), which is currently in the Phase 2 clinical trial, indicated for treating adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).

Key players

Key players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in 2014, Pfizer, Inc. and Collectis collaborated to develop novel CAR-T immunotherapies. The companies initiated Phase 1 clinical trial for UCART19 in 2016, indicated for pediatric patients with relapsed or refractory B-ALL.

Major players operating in the global acute lymphoblastic leukemia therapeutics market include, Talon Therapeutic, Inc., Sigma-Tau Pharmaceuticals, Inc., Novartis Pharmaceuticals, GlaxoSmithKline Plc., ERYTECH Pharma, Spectrum Pharmaceuticals, Inc., Pfizer Inc., Genzyme Corporation, F. Hoffmann-La Roche Ltd., Biogen Idec, Inc., Bristol-Myers Squibb, and Celgene Corporation.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1606

Market Taxonomy

On the basis of drug type, global acute lymphoblastic leukemia therapeutics market is segmented into:

• Chemotherapy Drugs
  • Nelarabine (Arranon)
  • Blinatumomab (Blincyto)
  • Clofarabine (Clolar)
  • Erwinia (Erwinase)
  • Pegaspargase (Oncaspar)
  • Vincristine (Marqibo)
  • Others
• Immunotherapy Drugs
  • Tisagenlecleucel (Kymriah)
• Targeted Therapy Drugs
  • Imatinib (Gleevec)
  • Dasatinib (Sprycel)
  • Nilotinib (Tasigna)
  • Others
• Others

On the basis of indication, global acute lymphoblastic leukemia therapeutics market is segmented into:

• Precursor B Cell ALL
• Mature B Cell ALL
• Precursor T Cell ALL

On the basis of distribution channel, the global acute lymphoblastic leukemia therapeutics market is segmented into:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

On the basis of region, the global acute lymphoblastic leukemia therapeutics market is segmented into:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Table of Content

Global Acute Lymphoblastic Leukemia Therapeutics Market Research Report
Section 1: Global Acute Lymphoblastic Leukemia Therapeutics Industry Overview
Section 2: Global Economic Impact on Acute Lymphoblastic Leukemia Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Acute Lymphoblastic Leukemia Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Acute Lymphoblastic Leukemia Therapeutics Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837